Established in 2014, Xantho Biotechnology Co., LTD is a research-oriented company specialized in developing new drugs in dermatology. The new drug GM-XANTHO, developed by Xantho Biotech, is a steroid-free topical ointment for the treatment of atopic dermatitis (AD). The efficacy and safety of GM-XANTHO in patients with atopic dermatitis are currently being studied in a double-blinded, placebo-controlled phase 2a clinical trial, and the interim analysis result will be available in 2023 Q2. We are looking to collaborate with pharmaceutical companies and investors to offer a better drug for AD patients. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization. For more information please visit https://xanthobio.com/en/ | Established in 2014, Xantho Biotechnology Co., LTD is a research-oriented company specialized in developing new drugs in dermatology. The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal topical cream which potentially has both therapeutic and preventive effects in inflammatory skin conditions including atopic dermatitis (AD) and plaque psoriasis. GM-XANTHO also has wound healing effect in skin conditions such as pressure ulcer, diabetic wound and burn wound. The IND for AD, plaque psoriasis and pressure ulcer have been approved by the USFDA. We are looking to collaborate with pharmaceutical companies to offer a better drug for AD patients. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization. For more information please visit https://xanthobio.com/en/ | The new drug GM-XANTHO developed by Xantho Biotechnology, is a non-steroidal topical cream which potentially has both therapeutic and preventive effects in inflammatory skin conditions including atopic dermatitis (AD) and plaque psoriasis. GM-XANTHO also has wound healing effects in skin conditions such as pressure ulcer and diabetic wound. The IND for AD, plaque psoriasis and pressure ulcer have been approved by the USFDA. The efficacy of GM-XANTHO is currently being studied in a double-blinded, placebo-controlled phase 2a clinical trial in mild-to-moderate AD patients (ClinicalTrials.gov ID NCT04369846). The results of the phase 2a study are expected to be available in 2025Q1. GM-XANTHO is available for out-licensing and we are seeking partners for drug development and commercialization. For more information please visit https://xanthobio.com/en/
WPD Pharmaceuticals
WPD Pharmaceuticals is a Polish biotech company developing innovative oncology therapies for high-mortality cancers. While initially focused on lethal brain tumors like glioblastoma, WPD has built a diverse pipeline of patented drug candidates (licensed from Wake Forest University) including cutting-edge antibody-drug conjugates. Our flagship ADC, WPD401, co-developed with Wake Forest, uniquely targets four tumor-specific receptors (IL-13Rα2, EphA2, EphA3, EphB2) found in some of the toughest-to-treat cancers. Originally designed for glioblastoma, WPD401 has shown potent activity in other aggressive tumors that overexpress these receptors – for example, triple-negative breast, pancreatic, and certain lung cancers – thereby broadening its clinical potential into multiple high-need indications. Backed by this innovative multi-target approach and encouraging preclinical results, WPD is now advancing toward clinical trials in the United States. We are actively seeking strategic partners to co-develop and unlock the full potential of our pipeline, with the aim of delivering life-changing therapies for patients with limited treatment options.
Wacker Biotech
WACKER BIOTECH is “THE MICROBIAL CDMO” – your partner of choice for process development and contract manufacturing of biopharmaceuticals (proteins, vaccines, live microbial products, plasmid DNA (pDNA)) using microbial hosts. Additionally, WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation, the nucleic acid expertise of Wacker Biotech combined with the lipid expertise of our partner CordenPharma ensures the best possible results for each of our client’s mRNA-focused projects. WACKER BIOTECH’s integrated service portfolio covers molecular biology, process / analytical development as well as GMP manufacturing of biologics for clinical and commercial supply. WACKER BIOTECH operates four state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands. Manufacturing lines are equipped with stainless steel fermentation vessels from 350 to 1500 liter as well as single-use bioreactors. Matching primary recovery, downstream and Fill & Finish capabilities are available to suit various clients’ needs across the development path (BSL 1 and 2). Additionally, a GMP cell-bank suite enables independent cell-bank production and storage capacity for client cell banks. In 2022 the German government selected Wacker Biotech and CordenPharma as joint bidders for the stand-by production of vaccines based on mRNA. Therefore, WACKER is now building a state-of-the-art mRNA competence and manufacturing center at its existing Halle, Germany site to complement its other existing sites in Jena, Germany, Amsterdam, the Netherlands and San Diego, California. The new capabilities at Wacker Biotech Halle will support end-to-end manufacturing of plasmid DNA, mRNA and LNP formulation under one roof. WACKER BIOTECH holds biomanufacturing certificates from the relevant authorities for all sites and follows the ICH Q7A guidelines for GMP-compliant production of biologics. The GMP production facilities in the Netherlands and Germany are approved by the EMA, U.S. FDA and/or ANVISA for commercial manufacturing. The WACKER BIOTECH U.S. site is currently preparing for a U.S. FDA inspection. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of Munich-based Wacker Chemie AG. | WACKER BIOTECH is the CDMO partner of choice for process development and manufacturing of biopharmaceuticals (therapeutic proteins, vaccines, live biotherapeutic products) based on microbial systems and for the entire manufacturing chain of pDNA, mRNA and lipid nanoparticle formulations. Our clients benefit from our decades of experience in complex protein-based therapeutics, vaccines, and specialty chemicals sectors, including partnering with the German government to respond to the Covid-19 pandemic. WACKER BIOTECH operates five state-of-the-art GMP facilities located in the U.S., Germany and The Netherlands. Manufacturing lines are equipped with stainless steel fermentation vessels from 350 to 1500 liter as well as single-use bioreactors. Matching primary recovery, downstream and Fill & Finish capabilities are available to suit various clients’ needs across the development path (BSL 1 and 2). WACKER BIOTECH provides R&D and GMP manufacturing services for advanced therapies as a one-stop-shop: from the production of plasmid and template DNA as starting material for mRNA through the IVT of mRNA and LNP formulation, the nucleic acid expertise of Wacker Biotech combined with the lipid expertise of our partner ensures the best possible results for each of our client’s mRNA-focused projects. In Amsterdam, NL, we jump-started mRNA manufacturing during the COVID-19 pandemic, making us a leading CDMO with hands-on GMP manufacturing experience of mRNA-based therapies, including validation GMP runs. With the addition of another cutting-edge competence center for mRNA actives in Halle, Germany, we have increased our RNA product manufacturing and LNP formulation capacity. In this dynamic field of advanced therapies, you will benefit from experienced, reputable partners validated by the German government. In close collaboration with universities and research institutions, WACKER’s corporate R&D team of over 200 researchers continuously develops new production platforms and technologies for all types of biopharmaceuticals, including pDNA, mRNA and LNPs. Competitive, outstanding solutions are our trademarks. Wacker Biotech GmbH, Wacker Biotech B.V. and Wacker Biotech US Inc. are wholly-owned subsidiaries of Munich-based Wacker Chemie AG. | Wacker Biotech is the expert biologics CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid and template DNA as a starting material for mRNA through the IVT of mRNA to lipid nanoparticle (LNP) formulation. We have the capability to produce at diverse scales up to 1500 L and recently quadrupled our mRNA production capacity with the completion of a new mRNA competence center in Halle, Germany. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization. We operate five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and the US (San Diego). Complementing our bioprocess development and manufacturing experts at these four sites is a team of dedicated research scientists leading continuous innovations and collaborations at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading chemistry advances. We have 30+ years of experience developing biologics to advance human and animal health. | Wacker Biotech is the expert biologics CDMO partner for process development and manufacturing of advanced therapies and vaccines, as well as live microbial products and recombinant proteins based on microbial systems. Our nucleic acid-based capabilities span the full manufacturing value chain, from the production of plasmid DNA as a starting material for RNA, to the IVT of RNA, to lipid nanoparticle (LNP) formulation. We also produce >97% supercoiled plasmids for AAV and LV delivery, and for direct application. In Wacker Biotech, you have a flexible partner delivering science-driven solutions and guidance from concept to commercialization. Our global footprint encompasses five GMP manufacturing facilities in Germany (Halle and Jena), the Netherlands (Amsterdam) and USA (San Diego), able to produce at diverse R&D, HQ and GMP grades, with scale-up to 1500 L. Complementing our bioprocess development and manufacturing experts at these sites is a team of dedicated research scientists leading continuous innovations and collaborations, and also providing nucleic acid contract research services, at our parent company’s R&D hub in Munich, Germany. Wacker Biotech is wholly owned by Munich-based Wacker Chemie AG, a publicly traded company founded in 1914 that pioneered some of the 20th century’s leading biochemistry advances. We have 30+ years of experience manufacturing biologics to advance human and animal health.
Vipragen Biosciences Private Limited
Vipragen Biosciences Pvt. Ltd. is a CRO certified by NGCMA for OECD-GLP to carry out safety studies for regulatory submissions. Additionally, the laboratory has been certified by AAALAC, NABL, and DCGI to support discovery research. Vipragen has deep scientific and research knowledge with a combined experience of over 150 years of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME. | Vipragen Biosciences Pvt. Ltd. is a globally recognized Contract Research Organization(CRO) which has been in the industry for more than a decade now and specializing in delivering comprehensive pre-clinical services to Global Drug Discovery companies. We are OECD-GLP certified and AAALAC accredited laboratory with the State-of-the-art Vivarium to carry out safety studies for regulatory submissions. Vipragen has deep scientific and research knowledge of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME. | Vipragen, a renowned Contract Research Organization (CRO), offers comprehensive services for global Pharmaceutical, Biopharmaceutical, Chemical, Nutraceutical and Medical Device companies. With over 12 years of experience, Vipragen Biosciences Private Limited is dedicated to delivering quality services. Under the leadership of Dr. Chandrashekaran Siddamadappa, Chairman and Managing Director, Vipragen has emerged as an Integrated Pre-clinical CRO, championing sustainability, integrity, safety and quality. Our state-of-the-art Vivarium holds Global certifications like OECD GLP, AAALAC and NABL, supported by multidisciplinary experts and equipped with 21CFR Part 11 compliance systems and processes. We ensure reliable data adhering to global standards with a focus on customer satisfaction. Our diverse portfolio includes Analytical, Toxicology and Chemistry services tailored to meet stringent regulatory submission requirements across the industries, ensuring compliance and transparency for clients across the industry spectrum.
Vetter
Vetter is a global leading contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany, with production facilities in Germany, Austria and the United States. The company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and compliance. Great importance is also given to social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com. | Vetter is a global leading contract development and manufacturing organization (CDMO), headquartered in Ravensburg, Germany, with production facilities in Germany, Austria and the United States. The company has long-term experience in supporting biotechnology and pharmaceutical customers both large and small. Vetter services range from early stage development support including clinical manufacturing, to commercial supply and numerous packaging solutions for vials, syringes and cartridges. As a leading solution provider, Vetter appreciates its responsibility to support the needs of its customers by developing devices that contribute to increased patient safety, convenience, and compliance. Great importance is also given to social responsibility including environmental protection and sustainability. | Vetter is a leading Contract Development and Manufacturing Organization (CDMO) with headquarters in Ravensburg, Germany, and production facilities in Germany, Austria, and the US. As a global player, the independent pharmaceutical service provider is also present in the Asia-Pacific markets of Japan, China, South Korea and Singapore with sales locations. Around the world renowned pharma and biotech companies benefit from decades of experience, high quality, modern technologies, reliability, and commitment of its 7,300 employees. In close collaboration with its customers, the Vetter team helps enable the supply to patients all over the world with medicines, many of which are vital. The CDMO provides support from drug product development through clinical and commercial filling to a wide range of assembly and packaging services for vials, syringes, and cartridges. With innovative approaches, Vetter develops prefilled drug-delivery systems together with its customers to continuously improve patient safety, comfort, and compliance. Vetter takes responsibility for sustainable practices and operates as a socially and ethically responsible corporate citizen. The CDMO is a member of the UN Global Compact and Science Based Target initiative (SBTi) and received platinum status in the renowned EcoVadis ranking. Multiple awards such as the CDMO Leadership Awards, Frost & Sullivan Customer Value Leadership Award and the recognition of Best Managed Company emphasize Vetter’s commitment to sustainable business. Founded in Ravensburg in 1950, the company remains family-owned to this day. For more information, visit www.vetter-pharma.com and follow Vetter on LinkedIn.
Veeda Lifesciences
For nearly two decades, Veeda Lifesciences has been a trusted partner in drug development, supporting pharmaceutical, biotech, and specialty healthcare companies in bringing innovative therapies to patients worldwide. Our global presence spans across 9 countries and 26 geographies, allowing us to offer localized expertise while maintaining a broad international reach. By combining scientific excellence, regulatory expertise, and cutting-edge technology, we ensure the execution of efficient, high-quality clinical trials that accelerate the drug development process. A Strategic Partner in Drug Development Veeda Lifesciences partners with innovator companies to navigate the intricate landscape of clinical research and drug development. Our comprehensive suite of services covers: Strategic Consulting: We provide expert guidance in trial design, regulatory pathways, and market access strategies, ensuring seamless progression from preclinical to clinical phases. Regulatory Support: Our regulatory affairs team assists with dossier preparation, regulatory submissions, and interactions with health authorities, streamlining the approval process. Operational Excellence: We offer end-to-end trial management solutions, including site selection, patient recruitment, monitoring, data management, and biostatistical analysis. Expertise Across Multiple Therapeutic Areas With deep domain expertise in key therapeutic areas, Veeda has played a pivotal role in advancing clinical research in: Oncology & Hematology: Our contributions include supporting one of the largest global multiple myeloma trials across 24 countries. By leveraging AI-driven patient recruitment strategies and real-world data, we optimize site selection and accelerate trial timelines. Dermatology: We have successfully executed clinical trials for novel dermatological therapies, addressing conditions such as psoriasis, atopic dermatitis, and skin cancers. Endocrinology & Metabolic Disorders: Veeda has been instrumental in conducting trials for diabetes, obesity, and other endocrine disorders, ensuring the safety and efficacy of new treatment modalities. Other Specialties: Our expertise extends to cardiovascular diseases, infectious diseases, autoimmune disorders, and rare diseases, enabling comprehensive clinical research solutions across various indications. Comprehensive Clinical Development Lifecycle Support Veeda Lifesciences offers integrated solutions across the entire clinical development lifecycle, ensuring scientific rigor, regulatory compliance, and operational efficiency at every stage: Early-Phase Studies: First-in-Human (FIH) and Phase I trials Bioavailability & bioequivalence (BA/BE) studies Pharmacokinetics (PK) and pharmacodynamics (PD) evaluations Adaptive trial designs to optimize early-stage decision-making Late-Stage Clinical Trials: Phase II-IV multi-regional clinical trials (MRCTs) Patient-centric study designs incorporating decentralized trial models Site feasibility assessments and accelerated patient enrollment strategies Global regulatory submissions and post-marketing surveillance Advanced Capabilities and Technology-Driven Approach Our commitment to technological innovation enhances trial efficiency and data integrity through: Bioanalytical Research & Central Lab Services: High-quality analytical testing for small molecules, biologics, and biosimilars, ensuring accurate pharmacokinetic and immunogenicity assessments. Digital Trial Management: AI-powered platforms for real-time data capture, electronic trial management, and remote monitoring, optimizing trial workflows. Patient Engagement Solutions: Digital tools to enhance patient retention, adherence, and real-world evidence generation, improving trial outcomes. Pharmacovigilance & Safety Monitoring: Comprehensive adverse event reporting and risk mitigation strategies, ensuring regulatory compliance and patient safety. Biopharmaceutical Development Expertise Veeda Lifesciences offers a comprehensive suite of services tailored to support the development of biopharmaceuticals, including biologics and biosimilars. Our expertise encompasses non-clinical testing solutions designed to ensure safety, efficacy, and regulatory compliance for complex biological therapies. Key Biopharma Services: Preclinical Research: We conduct rigorous preclinical studies to assess the safety and biological activity of biotherapeutic candidates, providing a solid foundation for clinical development. Bioanalytical Support: Our bioanalytical services include method development, validation, and high-throughput sample analysis, delivering precise data essential for regulatory submissions. Regulatory Consulting: We offer strategic guidance on regulatory pathways for biologics and biosimilars, assisting with dossier preparation and interactions with health authorities to streamline approvals. By integrating these services, Veeda Lifesciences ensures a seamless transition from discovery to market for biopharmaceutical products, upholding the highest standards of scientific integrity and patient safety. Beyond Clinical Trials: Integrated Research Solutions Veeda Lifesciences offers a holistic approach to drug development with a diverse range of research services, including: Preclinical Testing: In vitro and in vivo studies to assess drug safety, efficacy, and toxicity before clinical trials. Regulatory Consulting: Expert navigation of global regulatory landscapes, including US FDA, EMA, MHRA, DCGI, and other health authorities. Medical Writing & Scientific Documentation: Preparation of clinical study reports, investigator brochures, regulatory dossiers, and scientific publications to support regulatory approvals. A Trusted Partner for Advancing Life-Changing Therapies Veeda Lifesciences is committed to upholding the highest standards of scientific integrity, patient-centric research, and global regulatory excellence. Our collaborative approach, coupled with a strong emphasis on quality, innovation, and operational efficiency, makes us the preferred partner for companies seeking to bring transformative therapies to market. For more information, visit: Veeda Lifesciences
Valerian Chem Private Ltd
VProteomics, Valerian Chem Pvt. Ltd. to Showcase Advanced Mass Spectrometry Solutions at BIO International Convention 2025 We are excited to announce that VProteomics, Valerian Chem Pvt. Ltd. will be participating in the Innovative India Pavilion at the BIO International Convention 2025, taking place from June 16–19, 2025, at the Boston Convention & Exhibition Center, USA. As a leading provider of high-end mass spectrometry services, VProteomics specializes in proteomics, metabolomics, and clinical diagnostics, catering to academic institutions, medical researchers, and pharmaceutical companies. Our state-of-the-art laboratory in Noida is equipped with the latest mass spectrometry infrastructure, enabling us to deliver precise and reproducible results. Our Core Competencies: Discovery & Targeted Proteomics: Comprehensive protein analysis to elucidate complex biological processes. Advanced Metabolomics: In-depth metabolite profiling to understand metabolic pathways and disease mechanisms. Clinical Mass Spectrometry: Diagnostic services including biomarker detection, enzyme analysis, and toxicology testing, facilitating early disease diagnosis and personalized medicine. Biologics Characterization: Detailed analysis of biologic therapeutics to ensure efficacy and safety. We invite our esteemed clients, collaborators, and partners to visit our booth at the Innovative India Pavilion to explore potential collaborations and learn more about our contributions to the global biotech landscape. Event Details: Event: BIO International Convention 2025 Dates: June 16–19, 2025 Location: Boston Convention & Exhibition Center, Boston, USA Pavilion: Innovative India Pavilion For more information about our services, please visit our website: www.vproteomics.com We look forward to connecting with you in Boston!
Uniphar
Uniphar Group is a trusted global partner to pharma, medtech and biotech companies, working to improve patient access to medicines around the world. Uniphar’s team of experts harness the capabilities, infrastructure and expertise of a diversified pharmaceutical service provider with more than 57 years’ building success stories with 200+ multinational clients. Our understanding of the shifting market dynamics allows us to deliver tailored specialist services and solutions for our clients’ changing needs. Uniphar Pharma comprises of Uniphar | Clinical & Development, Uniphar | Access, Uniphar | Medical, and Uniphar | Commercial – together our combined capabilities make us your trusted partner to unlock access for your patients to innovative therapies and optimize value for brands globally. Partnering from clinical development to commercialisation, Uniphar’s global presence and in-depth market expertise remove barriers to launch and enhance pathways to life changing therapies. Connecting the dots from molecule to market.
UK Pavilion
The (UK’s) Department for Business and Trade (DBT) helps businesses export, drives inward and outward investment, negotiates market access and trade deals, and champions free trade. We are an international economic department, responsible for: • supporting and encouraging UK businesses to drive sustainable international growth • ensuring the UK remains a leading destination for international investment • opening markets, moulding the trade environment with new and existing partners which is free and fair • using trade and investment to underpin the government’s agenda for a Global Britain and its ambitions for prosperity, stability and security worldwide. | The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland and Wales and would like to work with you. We are joined by 16 inspired, innovative and international UK co-exhibitors eager to connect with you. | The UK’s Department for Business and Trade supports international investment into the UK and UK businesses to grow and export. Whether you’re interested in clinical research for innovative products, working with the UK’s world-leading universities, SMEs and spin outs, leveraging our globally-unique datasets or manufacturing complex products at pace and scale, the UK has a strong offer spanning Northern Ireland, Scotland, Wales and England and would like to work with you. This year, we are joined by 22 UK co-exhibitors eager to connect with you. | The Advanced Propulsion Centre (APC) is the organisation that pulls together exhibitors on the UK Pavilion who have advanced new technology and are looking for partner organisations to sell to or develop this technology with. The APC exists to ensure the UK remains competitive in the research, development and production of low emission technologies. Through our team of specialists we introduce those with good ideas to those who can take them to market, supporting through mentoring and providing access to funding. We are delivering a 10 year programme, launched in 2013. Born out of the collaboration between UK Government and industry, our organisation aims to save 50 million tonnes of CO2, safeguard or create 30,000 jobs in the UK and make £1 billion of match funding available to research and develop low emission propulsion technologies in the UK. | The Advanced Propulsion Centre UK (APC) collaborates with UK government, the automotive industry, and academia to facilitate driving research and investment in zero-emission vehicle manufacturing. Established in 2013 and jointly funded by the Department for Business and Trade (DBT) and the automotive industry, the APC accelerates the technologies that support the transition to zero-emission vehicle manufacturing and towards a net-zero automotive supply chain in the UK. With a proven track record, the APC has facilitated funding for 354 low-carbon and zero-emission projects involving 614 partners. Working with companies of all sizes, this funding since 2013 is estimated to have helped create or safeguard over 59,000 jobs in the UK. The technologies and products are projected to save over 425 million tonnes of CO2. The APC is committed to sustaining and enhancing the UK’s long-term automotive capabilities and investments through knowledge-sharing, collaboration, and innovation.